Daliresp, Daxas (roflumilast) is a small molecule pharmaceutical. Roflumilast was first approved as Daliresp on 2010-07-05. It is used to treat chronic obstructive pulmonary disease in the USA. It has been approved in Europe to treat chronic obstructive pulmonary disease. The pharmaceutical is active against cAMP-specific 3',5'-cyclic phosphodiesterase 4B. In addition, it is known to target cAMP-specific 3',5'-cyclic phosphodiesterase 4D. Daliresp's patents are valid until 2024-03-08 (FDA).
|Indication||chronic obstructive pulmonary disease|
|Drug Class||Antiasthmatics/antiallergics: type IV phosphodiesterase inhibitors|